جميع الدراسات
التوظيفالمرحلة 2تدخلي

A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease

This research study is testing a new daily medicine, etavopivat, for children and teenagers with sickle cell disease. We want to understand how safe it is and how it works in the body. We'll also be looking to see if it has any benefits for those taking it. Participants will take the medicine for 96 weeks, which is about 1 year and 10 months. During this time, they will have regular check-ups. The study aims to gather important information to help us understand if etavopivat could be a new treatment option for sickle cell disease.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 2
الراعي
Forma Therapeutics, Inc.
الهدف من التسجيل
95
ابدأ
12 يناير 2023
التاريخ المتوقع للانتهاء
08 Aug 2029

ما هو موضوع هذه الدراسة؟

Sickle cell disease is a lifelong condition that affects red blood cells. These cells, which are usually round and flexible, become stiff and C-shaped, like a sickle. This can block blood flow, causing pain, tiredness, and other serious health problems. It's a condition that can have a big impact on daily life, especially for young people.

This study, called "A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease," is looking at a new medicine called etavopivat. This medicine is designed to be taken once a day by mouth. The main goal is to understand if etavopivat is safe for children and teenagers with sickle cell disease and how their bodies handle the medicine, including how long it stays in their system.

Doctors are also interested in finding out if taking etavopivat can offer any improvements for people with sickle cell disease. By carefully studying this medicine, researchers hope to learn if it could become a helpful new treatment in the future. This is a "Phase 2" study, which means it's one of the earlier stages of testing a new medicine in people.

النقاط الرئيسية

  • This study is for children and teenagers with sickle cell disease.
  • It's testing a new daily medicine called etavopivat.
  • The main goals are to check the medicine's safety and how it works in the body.
  • Participation involves taking medicine daily for about 1 year and 10 months, with regular check-ups.
  • The study aims to see if etavopivat could be a new treatment option for sickle cell disease in the future.

من قد يكون مؤهلاً؟

This study is looking for children and teenagers with sickle cell disease. Participants must be between 6 months and 18 years old when they join the study. If you're under 18, your parent or guardian will need to give their permission for you to take part, and you'll also need to agree if you're old enough.

To be considered, you need to have a confirmed diagnosis of sickle cell disease, which can be shown by previous blood tests. Your haemoglobin level (a measure of red blood cells) also needs to be within a certain range. The study is specifically for those with more severe sickle cell disease, meaning you've had certain health issues related to your condition in the past year, such as several pain crises or hospital stays. Your doctor will be able to check all these details to see if you might be a good fit.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you between 6 months and 18 years old?
  2. Do you have a diagnosis of sickle cell disease?
  3. Has your sickle cell disease caused you to have certain serious health problems in the past year (like several pain crises or hospital stays)?
  4. Is your haemoglobin level within the required range (between 5.5 and 10.5 g/dL)?
  5. Are your parents or guardians willing to give permission for you to join?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you join this study, you'll be taking the study medicine, etavopivat, once a day by mouth for 96 weeks (that's about 1 year and 10 months). During this time, you'll have regular visits to the clinic so the study team can check on your health and how you're responding to the medicine. These visits will likely include physical exams, blood tests, and discussions about how you're feeling. After the 96-week treatment period, there will be one final check-up about a month later to make sure everything is okay.

المخاطر والفوائد المحتملة

Taking part in any medical study has potential benefits and risks. A possible benefit of this study is that etavopivat might help improve your sickle cell disease. However, it's also possible that the medicine may not help, or it might cause side effects. The study team will carefully monitor your health throughout the study to identify any problems as quickly as possible. You are free to leave the study at any time, for any reason, without it affecting your usual medical care.

المواقع (18)

  • مستشفى الأطفال المرضى
    الرمز البريدي المؤكد
    تورونتو، كندا· مكتمل
  • HCL-HOPITAL LYON SUD_Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)
    الرمز البريدي المؤكد
    ليون، فرنسا· لم يبدأ التوظيف بعد
  • APHP - Centre de Référence des Syndromes
    الرمز البريدي المؤكد
    باريس، فرنسا· لم يبدأ التوظيف بعد
  • Centre Hospitalier Universitaire de Rouen-Hopital Charles Nicolle
    غير مؤكد
    Roeun, France· لم يبدأ التوظيف بعد
  • KEMRI CRDR Siaya Clinical Research Annex, Country Referral Hospital
    الرمز البريدي المؤكد
    Siaya, Kenya· التوظيف
  • KEMRI-Walter-Reed Kericho
    الرمز البريدي المؤكد
    Kericho, Kenya· التوظيف
  • Kombewa Clinical Research Centre
    الرمز البريدي المؤكد
    Kisumu, Kenya· التوظيف
  • Ahero Clinical Trials Unit
    الرمز البريدي المؤكد
    Kisumu, Kenya· التوظيف
  • American University of Beirut Medical center
    الرمز البريدي المؤكد
    Beirut, Lebanon· التوظيف
  • Hospital Nini
    الرمز البريدي المؤكد
    Tripoli, Lebanon· التوظيف
  • University of Nigeria Teaching Hospital (UNTH)
    غير مؤكد
    Ituku-Ozalla, Nigeria· التوظيف
  • Lagos University Teaching Hospital, Lagos
    الرمز البريدي المؤكد
    Lagos, Nigeria· التوظيف

أسئلة شائعة

What is sickle cell disease?

Sickle cell disease is a genetic condition where red blood cells become stiff and C-shaped, which can block blood flow and cause pain and other health problems.

What is etavopivat?

Etavopivat is a new medicine being tested in this study. It's a tablet taken once a day by mouth for people with sickle cell disease.

كم مدة الدراسة؟

If you join, you will be taking the medicine for 96 weeks (about 1 year and 10 months), followed by a final check-up about 4 weeks later.

من يمكنه المشاركة في هذه الدراسة؟

The study is for children and teenagers with confirmed sickle cell disease, aged between 6 months and 18 years, who meet specific health criteria.

What do they hope to learn from this study?

Researchers want to learn if etavopivat is safe, how it works in the body, and if it can help improve the health of people with sickle cell disease.

كيفية معرفة المزيد

Novo Nordisk

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Study to Evaluate the Pharmacokinetics and Safety of Etavo… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.